

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

**FORM 6-K**

Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For the month of: May 2013

Commission File Number: 001-35776

**Acasti Pharma Inc.**

*(Name of Registrant)*

**545 PROMENADE DU CENTROPOLIS, SUITE 100**

**LAVAL, QUEBEC, CANADA H7T 0A3**

*(Address of Principal Executive Offices)*

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F [  ]

Form 40-F [  ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [  ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [  ]

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Acasti Pharma Inc.**

Date: May 29, 2013

By: /s/ Henri Harland

Name: Henri Harland

Title: Chief Executive Officer

---

## EXHIBIT INDEX

<u>Exhibit</u>	<u>Description of Exhibit</u>
99.1	Notice Declaring Intention to be Qualified Under National Instrument 44-101 - <i>Short Form Prospectus Distributions</i> ("NI 44-101")

**NOTICE DECLARING INTENTION TO BE QUALIFIED  
UNDER NATIONAL INSTRUMENT 44-101  
SHORT FORM PROSPECTUS DISTRIBUTIONS (“NI 44-101”)**

May 29, 2013

To: Autorité des marchés financiers, as notice regulator, and each of the other securities regulators in the provinces of Canada where the Issuer is a reporting issuer

Acasti Pharma Inc. (the “**Issuer**”) intends to be qualified to file a short form prospectus under NI 44-101. The Issuer acknowledges that it must satisfy all applicable qualification criteria prior to filing a preliminary short form prospectus. This notice does not evidence the Issuer’s intent to file a short form prospectus, to enter into any particular financing or transaction or to become a reporting issuer in any jurisdiction. This notice will remain in effect until withdrawn by the Issuer.

**ACASTI PHARMA INC.**

By: (signed) Xavier Harland  
Xavier Harland  
Chief Financial Officer